Related Experiment Video
Updated: Sep 17, 2025

Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
Published on: February 14, 2021
Exogenous estradiol increases cardiovagal baroreflex sensitivity during a hypertensive stimulus in premenopausal
Rauchelle E Richey1, Jennifer Ann Miner1, Jonathon C Miner1
1Department of Human Physiology, University of Oregon, Eugene, Oregon, United States.
Abstract:
Women have a greater reduction in cardiovagal baroreflex sensitivity (CVBRS) as they age which contributes to an elevated cardiovascular disease risk. One potential contributor to the attenuated CVBRS may be reductions in estrogen. Therefore, we tested the hypothesis that isolated estradiol (E2) and combined E2 and progesterone (P4) would increase CVBRS to the same extent. To examine the acute effects of E2 and P4 on CVBRS in healthy premenopausal women, we used a gonadotropin-releasing hormone antagonist to suppress endogenous sex hormones. We tested 29 young adult women over 10-12 days of hormone manipulation. After 4 days of hormone suppression, participants were given either 0.1-0.2 mg transdermal estradiol (E2) or 200 mg oral micronized progesterone (P4) per day. Following 3-4 days of isolated hormones, combined hormones (200 mg of progesterone and 0.1-0.2 mg estradiol) were administered. CVBRS was assessed during a modified Oxford protocol approximately 4 days following each change in hormones. Overall CVBRS was determined as the slope of the response between the R-R interval and systolic blood pressure. CVBRS slope during the hypotensive (sodium nitroprusside) and hypertensive (phenylephrine) phases of the modified Oxford were also assessed. There was no change in the overall R-R interval or hypotensive CVBRS during any of the hormone trials. Interestingly, the E2 group's CVBRS increased in response to the hypertensive stimulus, whereas the P4 group had no change. These data suggest that estradiol alone augments CVBRS to a hypertensive stimulus, but progesterone alone and combined E2 and P4 do not change CVBRS.NEW & NOTEWORTHY Attenuated cardiovagal baroreflex sensitivity is associated with cardiovascular disease. Female sex hormones have a significant impact on the development of cardiovascular disease across the lifespan. Using an experimental model of hormone suppression and add-back, estradiol add-back alone increased cardiovagal baroreflex sensitivity to a hypertensive stimulus unlike the other hormone manipulation conditions. These data suggest that estradiol alone plays a significant role in cardiovagal baroreflex sensitivity and reductions may contribute to potential cardiovascular disease development.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
14:26A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Related Concept Videos
Neural Regulation of Blood Pressure
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Factors Influencing Heart Rate
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
Hypertension and Regulation of Blood Pressure
Regulation of Heart Rates
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System